Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells

Cancer Science

Volumn 103, Issue 2, 2012, Pages 334-341

  Procházka, Pavel ^a,d   Libra, Antonín ^c   Zemanová, Zuzana ^b   Hřebačková, Jana ^a   Poljaková, Jitka ^a,b   Hraběta, Jan ^a   Bunček, Martin ^c   Stiborová, Marie ^b   Eckschlager, Tomáš ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Generi Biotech sro   (Czech Republic)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DNA TOPOISOMERASE; ELLIPTICINE; PROTEIN BCL 2; SPERMINE; SPERMINE SYNTHETASE; UNCLASSIFIED DRUG;

AEROBIC CAPACITY; AEROBIC REACTOR; ARTICLE; CANCER CELL CULTURE; CELL RESPIRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE OVEREXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NEUROBLASTOMA; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; DNA TOPOISOMERASES; DRUG RESISTANCE, NEOPLASM; ELLIPTICINES; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84856507253     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02137.x     Document Type: Article

References (41)

1. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-11.
2. Navalkele P, O'Dorisio MS, O'Dorisio TM, Zamba GK, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer 2011; 56: 50-7.
3. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58: 5396-405.
4. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011; 56: 578-83.
5. Emanuel SL, Chamberlin HA, Cohen D. Antimitotic drugs cause increased tumorigenicity of multidrug resistant cells. Int J Oncol 1999; 14: 487-94.
6. Poljakova J, Eckschlager T, Hrabeta J et al. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol 2009; 77: 1466-79.
7. Stiborova M, Poljakova J, Martinkova E et al. Ellipticine cytotoxicity to cancer cell lines: a comparative study. Interdiscip Toxicol 2011; 4: 98-105.
8. Singh MP, Hill GC, Peoc'h D, Rayner B, Imbach JL, Lown JW. High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 1994; 33: 10271-85.
9. Auclair C. Multimodal action of antitumor agents on DNA: the ellipticine series. Arch Biochem Biophys 1987; 259: 1-14.
10. Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 1995; 270: 14998-5004.
11. Stiborova M, Rupertova M, Frei E. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim Biophys Acta 2011; 1814: 175-85.
12. Kotchetkov R, Cinatl J, Blaheta R et al. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 2003; 104: 36-43.
13. Bedrnicek J, Vicha A, Jarosova M et al. Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Neoplasma 2005; 52: 415-9.
14. de Cremoux P, Jourdan-Da-Silva N, Couturier J et al. Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 2007; 48: 311-7.
15. Cinatl J Jr, Vogel JU, Cinatl J et al. Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int J Cancer 1996; 65: 90-6.
16. Cinatl J Jr, Cinatl J, Kotchetkov R et al. Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs. Anticancer Res 2000; 20: 853-9.
17. Schlegel RA, Stevens M, Lumley-Sapanski K, Williamson P. Altered lipid packing identifies apoptotic thymocytes. Immunol Lett 1993; 36: 283-8.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25: 402-8.
19. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods 2003; 31: 265-73.
20. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
21. Ritchie ME, Silver J, Oshlack A et al. A comparison of background correction methods for two-colour microarrays. Bioinformatics 2007; 23: 2700-7.
22. Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 2011; 17: 89-95.
23. Raguz S, Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 2008; 99: 387-91.
24. Kotchetkov R, Driever PH, Cinatl J et al. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol 2005; 27: 1029-37.
25. Pang E, Hu Y, Chan KY et al. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells. Lab Invest 2005; 85: 664-74.
26. Carlson KM, Gruber A, Liliemark E, Larsson R, Nordenskjold M. Characterization of drug-resistant cell lines by comparative genomic hybridization. Cancer Genet Cytogenet 1999; 111: 32-6.
27. Prochazka P, Hrabeta J, Vicha A, Eckschlager T. Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine. Cancer Genet Cytogenet 2010; 196: 96-104.
28. Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle 2007; 6: 2782-7.
29. Murakami T, Shibuya I, Ise T et al. Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int J Cancer 2001; 93: 869-74.
30. Martinez-Zaguilan R, Raghunand N, Lynch RM et al. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol 1999; 57: 1037-46.
31. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Diz PG, Rey JM, Garcia-Garcia A. Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases. Cancer Lett 2010; 295: 135-43.
32. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126-32.
33. 2-oxide. Cancer Res 2004; 64: 8374-80.
34. Blaheta RA, Daher FH, Michaelis M et al. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. BMC Cancer 2006; 6: 294.
35. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci U S A 1994; 91: 3497-504.
36. Callaghan R, Stafford A, Epand RM. Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties. Biochim Biophys Acta 1993; 1175: 277-82.
37. Liang X, Huang Y. Physical state changes of membrane lipids in human lung adenocarcinoma A(549) cells and their resistance to cisplatin. Int J Biochem Cell Biol 2002; 34: 1248-55.
38. Janne J, Alhonen L, Pietila M, Keinanen TA. Genetic approaches to the cellular functions of polyamines in mammals. Eur J Biochem 2004; 271: 877-94.
39. Ikeguchi Y, Mackintosh CA, McCloskey DE, Pegg AE. Effect of spermine synthase on the sensitivity of cells to anti-tumour agents. Biochem J 2003; 373: 885-92.
40. Grandgirard N, Ly-Sunnaram B, Ferrant D et al. Impact of topoisomerase II alpha and spermine on the clinical outcome of children with acute lymphoblastic leukemia. Leuk Res 2004; 28: 479-86.
41. Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK. DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr Cancer Drug Targets 2010; 10: 758-71.